Tiveron Mauro C, Alió Del Barrio Jorge L, Kara-Junior Newton, Plaza-Puche Ana Belén, Abu-Mustafa Sabat K, Zein Ghassan, Alió Jorge L
J Refract Surg. 2017 Aug 1;33(8):538-544. doi: 10.3928/1081597X-20170616-02.
To assess visual and refractive outcomes of toric iris-claw phakic intraocular lens (IOL) implantation in patients who had previously undergone deep anterior lamellar keratoplasty (DALK).
Retrospective case series including 24 eyes of 24 patients implanted with toric Artiflex or Artisan (Ophtec BV, Groningen, Holland) phakic IOL following DALK for keratoconus. During a 12-month follow-up, the main outcome measures were uncorrected and corrected distance visual acuities (UDVA and CDVA), refractive error components, topographic parameters, and endothelial cell count. Alpins vectorial analysis was performed.
At the last follow-up, the spherical equivalent (SE) was within ±0.50 diopters (D) in 71% of eyes and within ±1.00 D in 92% of eyes. Mean refractive astigmatism was reduced from -4.92 ± 1.55 D (range: -2.50 to -8.00 D) preoperatively to -0.66 ± 0.61 D (range: -2.00 to 0.00 D) after treatment, and 76.5% of cases were within ±1.00 D. No significant differences (P = .123) were detected in spherical equivalent values between 3- and 12-month follow-up visits. No eyes lost lines in CDVA, and 54% of eyes gained one or more lines. Postoperative UDVA was 20/40 or better in 88% of eyes. Efficacy and safety indexes at 12 months were 0.93 and 1.00, respectively. Mean endothelial cell loss was 6.10% at 12 months postoperatively. No intraoperative or postoperative complications were noted over the follow-up period.
The implantation of a toric iris-claw phakic IOL has shown high efficacy and safety in this series and may be considered as a reasonable option for the management of refractive errors after DALK. [J Refract Surg. 2017;33(8):538-544.].
评估在先前接受过深板层角膜移植术(DALK)的患者中植入有晶状体眼环形虹膜夹人工晶状体(IOL)后的视觉和屈光效果。
回顾性病例系列研究,纳入24例患者的24只眼,这些患者在因圆锥角膜接受DALK术后植入了Artiflex或Artisan(荷兰格罗宁根Ophtec BV公司)有晶状体眼环形IOL。在12个月的随访期间,主要观察指标为未矫正和矫正远视力(UDVA和CDVA)、屈光不正成分、地形图参数和内皮细胞计数。进行了Alpins矢量分析。
在最后一次随访时,71%的眼球镜等效度(SE)在±0.50屈光度(D)以内,92%的眼在±1.00 D以内。平均屈光性散光从术前的-4.92±1.55 D(范围:-2.50至-8.00 D)降至治疗后的-0.66±0.61 D(范围:-2.00至0.00 D),76.5%的病例在±1.00 D以内。在3个月和12个月随访时的球镜等效度值之间未检测到显著差异(P = 0.123)。没有眼的CDVA下降,54%的眼提高了一行或多行。88%的眼术后UDVA为20/40或更好。12个月时的疗效和安全指数分别为0.93和1.00。术后12个月平均内皮细胞丢失率为6.10%。在随访期间未观察到术中或术后并发症。
在本系列研究中,植入有晶状体眼环形虹膜夹人工晶状体显示出高疗效和安全性,可被视为DALK术后屈光不正治疗的合理选择。[《屈光手术杂志》。2017;33(8):538 - 544。]